Laughing gas may offer rapid relief for treatment-resistant depression

A new comprehensive analysis indicates that nitrous oxide, commonly known as laughing gas, provides rapid relief for adults suffering from severe forms of depression. The findings suggest that this common anesthetic could serve as a fast-acting alternative for patients who have not responded to standard antidepressant medications. These results were detailed in a paper published recently in eBioMedicine.

Depression is a pervasive condition that affects hundreds of millions of people globally. It disrupts biological and environmental systems to cause severe disability and reduced quality of life. The economic burden is immense, with costs related to poor mental health estimated to exceed hundreds of billions of euros annually in Europe alone.

Standard treatments typically focus on regulating monoamines, such as serotonin and noradrenaline. While these medications help many, they fail to provide relief for nearly half of all patients. They also typically take several weeks to become effective. This delay and high rate of failure have prompted researchers to look for alternatives that target different brain pathways.

One area of focus is the glutamatergic system, which manages excitatory signaling in the brain. Drugs that block specific receptors in this system, known as NMDA receptors, have shown the ability to lift mood quickly. Ketamine is a well-known example of this type of compound, but its use can be complicated by significant side effects.

Nitrous oxide also interacts with these NMDA receptors. To understand its potential better, a team of researchers led by Kiranpreet Gill and Professor Steven Marwaha from the University of Birmingham and the University of Oxford conducted a comprehensive study. Their goal was to assess the efficacy, safety, and clinical relevance of the gas for treating major depressive disorder and treatment-resistant depression.

Free daily newsletter

The researchers employed a multi-pronged approach to evaluate the existing evidence. They conducted a systematic review and meta-analysis, which involved combing through medical databases to identify all relevant clinical trials. The team also utilized a technique called evidence mapping to visualize the current landscape of ongoing and completed research.

The investigators aggregated data from seven completed randomized controlled trials involving nearly 250 participants. These studies included patients with major depressive disorder, treatment-resistant depression, and bipolar depression. By pooling the statistical data from these separate trials, the team could measure the overall effectiveness of the gas compared to placebos.

The analysis revealed that patients who inhaled nitrous oxide experienced a significant reduction in depressive symptoms shortly after administration. These improvements were statistically detectable at two hours and twenty-four hours after the treatment session. The speed of this response stands in contrast to traditional oral antidepressants which function on a much slower timeline.

However, the study data showed that for single sessions, the antidepressant effects typically diminished after one week. The benefits were transient rather than permanent following a solitary dose. The researchers then examined the impact of receiving multiple treatments over time.

The data suggested that repeated sessions over several weeks led to more durable symptom reduction compared to a single dose. This indicates that a cumulative effect may occur with sustained treatment protocols. The review also compared gas mixtures containing twenty-five percent nitrous oxide against those with fifty percent.

Both concentrations reduced symptoms more effectively than a placebo. There was evidence of a dose-response relationship, where the higher concentration provided greater symptom relief. However, the higher dose was also associated with a higher rate of side effects.

The safety analysis showed that side effects were generally mild and temporary. Commonly reported issues included nausea, dizziness, and headaches. These physical sensations usually resolved spontaneously shortly after the gas administration stopped.

No serious adverse events requiring emergency medical intervention were recorded in the reviewed trials. When comparing the two dosage levels, the twenty-five percent concentration resulted in significantly fewer instances of nausea and vomiting. This suggests lower doses might offer a better balance of tolerability and efficacy for some patients.

Beyond the statistical analysis of past trials, the authors used evidence mapping to assess the broader research pipeline. They reviewed protocols for ongoing and planned studies to identify trends and gaps. This assessment highlighted that research has largely focused on single-session protocols in adults.

The mapping process revealed a scarcity of data regarding long-term outcomes. There are also very few studies examining the use of this treatment for adolescents or for bipolar depression. The team also highlighted a lack of standardization in how the gas is delivered and how outcomes are measured across different experiments.

The biological mechanisms behind the success of nitrous oxide are multifaceted. The gas blocks NMDA receptors, which helps restore disrupted glutamate signaling often implicated in depression. It also increases blood flow to the brain, which may improve oxygen and nutrient delivery to neural tissues.

Some evidence suggests the gas may reduce hyperactivity in the default mode network. This is a brain network linked to self-referential thought and rumination. Dampening activity in this area could help alleviate the negative thought loops that characterize depressive states.

Additionally, nitrous oxide modulates the opioid and dopamine systems. These systems are central to regulating mood and sensitivity to reward. By engaging these pathways, the treatment may help address core symptoms such as the inability to feel pleasure or a lack of motivation.

The study offers a comparison to ketamine, another rapid-acting agent. While both target NMDA receptors, ketamine appears to have a stronger and longer-lasting effect after a single dose. However, ketamine is also associated with more intense side effects, such as dissociation and cardiovascular changes.

Nitrous oxide appears to induce weaker NMDA inhibition. This likely contributes to its milder side effect profile. The trade-off appears to be a shorter duration of antidepressant action requiring potentially more frequent administration.

While the results are promising, there are limitations to the current evidence base. The total number of participants across all reviewed studies remains relatively small. This limits the statistical power to detect subtle differences between patient subgroups.

The transient nature of the relief provided by a single dose suggests that nitrous oxide may not be a standalone cure. It might function better as part of a maintenance schedule or a bridge to other therapies. Researchers must determine the optimal frequency of sessions to maintain the benefits.

Blinding is another methodological challenge in these types of experiments. Because nitrous oxide causes distinct physical sensations, participants often guess correctly that they are not in the placebo group. This awareness can influence patient reporting of symptom improvement.

Future studies will need to address these issues with rigorous designs and larger groups of participants. Researchers need to standardize how they measure remission and response rates. This would allow for better comparisons between different clinical trials.

Kiranpreet Gill, a PhD researcher funded by the Medical Research Council at the University of Birmingham and first author of the study, said: “Depression is a debilitating illness, made even more so by the fact that antidepressants make no meaningful difference for almost half of all patients diagnosed with it. There is a growing body of research on repurposing treatments from other clinical domains to alleviate low mood. This study brings together the best possible evidence indicating that nitrous oxide has the potential to provide swift and clinically significant short-term improvements in patients with severe depression.”

She continued regarding the implications for future work. “Our analyses show that nitrous oxide could form part of a new generation of rapid-acting treatments for depression. Importantly, it provides a foundation for future trials to investigate repeated and carefully managed dosing strategies that can further determine how best to use this treatment in clinical practice for patients who don’t respond to conventional interventions.”

The safety of long-term use also requires further investigation to ensure there are no cumulative negative effects. Misuse of the gas recreationally is known to cause vitamin B12 deficiency and potential nerve damage. Clinical protocols would need to account for these risks through supplementation or monitoring.

Professor Steven Marwaha from the University of Birmingham, the senior author, commented on the significance of the work. “This is a significant milestone in understanding the potential of nitrous oxide as an added treatment option for patients with depression who have been failed by current treatments.”

“This population has often lost hope of recovery, making the results of this study particularly exciting. These findings highlight the urgent need for new treatments that can complement existing care pathways, and further evidence is needed to understand how this approach can best support people living with severe depression.”

The study, “Nitrous oxide for the treatment of depression: a systematic review and meta-analysis,” was authored by Kiranpreet Gill, Angharad N. de Cates, Chantelle Wiseman, Susannah E. Murphy, Ella Williams, Catherine J. Harmer, Isabel Morales-Muñoz, and Steven Marwaha.